Advertisement

FDA gives emergency use authorization for Regeneron COVID-19 treatment

"Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.

Advertisement

The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.

It's approved to treat mild and moderate COVID-19 for high-risk adults and pediatric patients ages 12 and older, the FDA said.

Advertisement

The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.

"Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” FDA Commissioner Dr. Stephen Hahn said in a statement.

Monoclonal antibodies — proteins made in labs — help the immune system fight off pathogens.

Video: Pfizer, BioNTech seek emergency use of COVID-19 shots in US

President Donald Trump celebrated the dose of experimental monoclonal antibodies he was given to help address his case of COVID-19. He said he thinks it helped him vanquish his coronavirus infection in record time.

CNN contributed.